A modified BPC-157 derivative engineered for oral bioavailability — and the compound everyone's asking about since FDA enforcement shut down injectable BPC-157 compounding. Here's what the evidence actually shows (and what it doesn't).
The BPC-157 derivative built to survive oral delivery — and avoid the FDA's crosshairs.
PDA is BPC-157 with an arginate salt modification — arginine residue added to the C-terminus to improve GI stability and intestinal permeability. The core 15-amino-acid sequence is preserved.
BPC-157 survives gastric acid reasonably well, but absorption across intestinal epithelium is the bottleneck. The arginate modification is theorized to improve this — though head-to-head oral absorption data is lacking.
PDA is formulated as a dietary supplement ingredient — not a compounded drug. This sidesteps the FDA's 503A/503B bulk ingredient restrictions that banned injectable BPC-157 from compounders in early 2026.
BPC-157 works primarily through the NO-system, growth hormone receptor modulation, and VEGF upregulation. PDA is expected to share this mechanism — the modification targets delivery, not pharmacology.
PDA was introduced by supplement companies responding to the FDA enforcement environment. It is not a novel academic discovery — it's a commercially-driven formulation innovation.
Available as oral capsules from select supplement vendors. Not FDA-approved, not scheduled, not a controlled substance. Research-chemical / supplement gray market territory as of 2026.
The FDA enforcement timeline that created the market for PDA.
Where PDA improves on BPC-157, where it falls short, and what's still unknown.
| Factor | Injectable BPC-157 | Pentadeca Arginate (PDA) |
|---|---|---|
| Core sequence | 15 amino acids (GEPPPGKPADDAGLV) | Same core sequence + arginate modification |
| Route | Subcutaneous or intramuscular injection | Oral capsule |
| Bioavailability (oral) | ~Low (acid-stable but poor epithelial absorption) | ~Improved (arginate theorized to aid absorption — unconfirmed) |
| Published human trials | None (animal-only literature) | None |
| Animal research base | 500+ studies (30+ years) | Minimal — extrapolated from BPC-157 |
| FDA legal status (US) | Restricted — Category 2 bulk substance | Supplement-friendly — not on restricted list |
| Ease of use | Requires reconstitution, cold storage, injection | Oral capsule — no needles or storage requirements |
| Systemic vs local effect | Both — injection site + systemic | Primarily systemic via oral absorption (GI-local effects plausible) |
| Long-term safety data | Extensive animal data, no human LT studies | No long-term data of any kind |
| Typical cost | Was $30–80/month from compounders (now largely unavailable) | $50–120/month from supplement vendors |
What exists, what doesn't, and how to think about extrapolated data.
BPC-157 Literature: The mechanistic claims behind PDA rest on the BPC-157 body of work, primarily from Dr. Predrag Sikiric's lab at the University of Zagreb (30+ years of animal research).
Key domains: tendon/ligament healing, muscle recovery, gut protection (IBD, NSAID gastroprotection), CNS neuroprotection, angiogenesis. See the full BPC-157 research breakdown for citations.
⚠️ No PubMed results exist for "Pentadeca Arginate" as a specific compound as of March 2026.
Community-derived dosing extrapolated from BPC-157 oral protocols. No clinical dosing studies exist.
Once daily, on an empty stomach. Starting low allows assessment of individual response before escalating.
1 mg/day is the most frequently reported dose in community protocols — split AM/PM or single dose.
2 mg/day reported by some users for injury recovery. No evidence this is more effective — increased cost and unknown risk.
Typical cycle lengths mirror BPC-157 protocols: 4–8 weeks for acute use, up to 12 weeks ongoing. No data on optimal duration.
Fasted state recommended — take 30–60 minutes before food. The theoretical absorption benefit of the arginate modification may be diminished when taken with a meal.
Oral capsules — typically 500 mcg per capsule. No reconstitution needed. Store per manufacturer guidance (room temp or refrigerated depending on vendor).
Most community protocols cycle rather than run continuously — 4–8 weeks on, 4 weeks off. This is precautionary given the complete absence of long-term safety data.
BPC-157 has an unusually favorable animal safety profile — but that's not the same as PDA safety data.
Realistic candidate assessment — not a sales pitch.
If injectable BPC-157 worked for you and you're looking for a legal continued option, PDA is the most direct alternative. You're extrapolating from known personal response, which is more information than the general population has.
BPC-157's best-evidenced use case. PDA is a reasonable consideration for someone who can't access injectable BPC-157, understands the evidence gap, and has tried conventional options.
Oral delivery may actually be advantageous for gut-targeted effects — the compound is present in the GI tract where BPC-157 is naturally found. IBD, leaky gut, gastric ulcer contexts.
Anyone looking for evidence-backed clinical outcomes, anyone risk-averse about novel compounds, anyone with cancer history, or anyone expecting it to work identically to well-studied injectable BPC-157.
What we know. What we don't.
Dig deeper into BPC-157, healing peptides, and the regulatory landscape.
Products relevant to an oral peptide protocol.
Affiliate links help support MeetPeptide at no extra cost to you.